Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03840863
Other study ID # 19-02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 6, 2019
Est. completion date July 30, 2020

Study information

Verified date November 2020
Source University of the Pacific
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many people use energy drinks (EDs) regularly, but the overall health concerns are still unknown. There are many energy drink products that contain a mixture of caffeine and other energy-boosting ingredients and supplements which can affect parameters related to the heart, blood pressure and blood glucose. Several previous studies have shown that energy drinks may affect heart rhythm and blood pressure significantly. As energy drinks are sugar-sweetened beverages, long-term use may also affect the body's metabolism, including cholesterol, blood sugars, and weight. The purpose of this study is to learn if drinking energy drinks everyday may affect a person's cardiometabolic health.


Description:

The popularity of energy drinks (EDs) have increased over the last few decades due to their purported benefits as mental and physical performance enhancements. While caffeine is a major ingredient in most EDs (ranging from 80 mg to 500 mg per drink), they may also contain various supplements, such as guarana, taurine, ginseng, B vitamins, gluconolactone, yohimbe, carnitine, and bitter orange, as well as high amount of sugar (ranging from 25-50 grams). The United States Food and Drug Administration (FDA) has cited that a daily intake of 400 mg caffeine (approximately 4-5 cups of coffee) in adults is generally safe and not associated with dangerous, negative effects. The Substance Abuse and Mental Health Services Administration reported a doubling of emergency department visits involving EDs from 10,068 visits in 2007 to 20,783 visits in 2011. Commonly reported adverse reactions include insomnia, nervousness, headache, tachycardia, and seizures. Currently, the health effects of long-term ED use remain unknown. This study is a proof-of-concept, prospective trial that aims to evaluate the effects of chronic ED consumption on cardiometabolic parameters in a healthy population. Subjects will consume two cans (16 oz.) of an energy drink daily for 4 weeks. The study will assess any changes in blood pressure (BP), electrocardiographic (ECG) parameters, blood glucose, cholesterol, weight, body mass index (BMI), and body fat composition before and after consuming EDs for 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date July 30, 2020
Est. primary completion date June 20, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Healthy adults aged 18 - 40 years - Participants willing to adhere to study drink schedule (28 days) Exclusion Criteria: - Naïve caffeine consumers (< 2 cups of coffee [or equivalent caffeine intake] per week) - Chronic medical conditions including cardiovascular disease (known history of cardiac arrhythmias, family history of premature sudden cardiac death before age 60, cardiomyopathy, atherosclerosis), smoking, renal or hepatic dysfunction - Prolonged corrected QT (QTc) interval - History of substance abuse, including alcohol - Concurrent use of prescription drugs or over-the-counter products that may interact with study drinks (with the exception of oral contraceptives that have been used for over 1 month) - Baseline Blood Pressure greater than 140/90 mmHg - Baseline fasting blood glucose greater than 126 mg/dL or random blood glucose greater than 200 mg/dL - Females only: pregnancy or lactation, or planning to get pregnant within next 28 days

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Commercially-Available Energy Drink
Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.

Locations

Country Name City State
United States University of the Pacific Stockton California

Sponsors (1)

Lead Sponsor Collaborator
University of the Pacific

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in blood pressure before and 1 hour after energy drink consumption Measuring acute changes in peripheral systolic blood pressure before and 1 hour after energy drink consumption 1 hour
Primary Change in blood pressure before and after 4 weeks of energy drink consumption Measuring chronic changes in peripheral systolic blood pressure before and 4 weeks after energy drink consumption 4 weeks
Secondary Change in QTc Interval before and after 1 hour of energy drink consumption Measuring change in QTc interval via electrocardiogram before and after 1 hour of energy drink consumption 1 hour
Secondary Change in QTc Interval before and after 4 weeks of energy drink consumption Measuring change in QTc interval via electrocardiogram before and after 4 weeks of energy drink consumption 4 weeks
Secondary Change in fasting blood glucose before and after 4 weeks of energy drink consumption Measuring the change in fasting blood glucose before and after 4 weeks of energy drink consumption 4 weeks
Secondary Change in fasting lipid panel parameters before and after 4 weeks of energy drink consumption Measuring the changes in total cholesterol (TC), high-density lipoprotein (HDL), triglyceride (TG), and calculated low-density lipoprotein (LDL-C) levels before and after 4 weeks of energy drink consumption 4 weeks
Secondary Change in Body Mass Index before and after 4 weeks of energy drink consumption Measuring the change in Body Mass Index (BMI) before and after 4 weeks of energy drink consumption 4 weeks
Secondary Change in Body Fat Analysis before and after 4 weeks of energy drink consumption Measuring the changes in Body Fat Analysis before and after 4 weeks of energy drink consumption, including percentage of body fat, fat mass, muscle mass, and fat in trunk 4 weeks
Secondary Change in Serum Creatinine before and after 4 weeks of energy drink consumption Measuring the change in Serum Creatinine before and after 4 weeks of energy drink consumption 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)